Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone vs hydrocortisone for oxygen need reduction in preterm infants with bronchopulmonary dysplasia
IRCT20201222049802N3Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexamethasone and hydrocortisone in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoint: Reduction in need for oxygen. Started Sep 2021; status: completed.
02
Drugs
dexamethasonehydrocortisone
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on IRCT20201222049802N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201222049802N3.